The CEO's reported 2025 total pay of $26.5 million is substantially inflated by a one-time share award of approximately $19.1 million (reported value) granted in December 2025 to partially compensate for a multi-year pay deficit — the company's own compensation consultant confirmed the CEO had been paid in the bottom quartile of peers cumulatively from 2022 to 2025 despite top-quartile stock performance. Stripping out this remediation award, ongoing annual pay is consistent with what would be expected for a CEO at an $8 billion specialty chemicals company with ESI's strong track record. The pay-for-performance alignment is solid: ESI's 3-year total return of +88.3% beats the peer group median of -8.0% by over 96 percentage points, annual bonus payouts reflected genuine above-target operating performance, and the long-term incentive structure includes meaningful multi-year performance conditions tied to earnings growth and a relative total return modifier. With 93.92% shareholder support in the prior year and a well-structured ongoing program, a FOR vote is warranted.

Non-audit fees (tax services of $0.7 million) represent approximately 12.7% of audit fees ($5.5 million), well below the 50% threshold that would raise independence concerns. PwC is a Big Four firm appropriate for a company of ESI's size and complexity. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire per policy, and no material restatements are noted.